ACRO urges FDA to expedite modernizing clinical trials | Bioeconomy report sets White House agenda | FDA approves Novartis' Afinitor as renal angiomyolipoma treatment
 
April 27, 2012
FDLI SmartBrief
News for the food and drug law community
SIGN UP|FORWARD|ARCHIVE|ADVERTISE

Drugs & Biologics
ACRO urges FDA to expedite modernizing clinical trials
The Association of Clinical Research Organizations asked the FDA to accelerate the modernization of regulations covering U.S. clinical trials. Though there have been some advances in "developing basic building blocks," product development is still expensive, unproductive and slow, ACRO said. The group suggested the FDA hire a chief innovation officer who has the power to authorize new approaches to trials. PharmaTimes (U.K.) (4/26) Share: Email
Bioeconomy report sets White House agenda
The National Bioeconomy Blueprint released Thursday lays out proposals to encourage growth in bio-based industries. Among the initiatives are a USDA expansion of the federal BioPreferred procurement program, an effort to expand FDA medical device reviewers' knowledge of emerging technologies and a Homeland Security program to use genomics-based microbial analysis. GenomeWeb Daily News (free registration) (4/26), Forbes (4/26) Share: Email
FDA approves Novartis' Afinitor as renal angiomyolipoma treatment
The FDA approved Novartis' Afinitor, or everolimus, to treat renal angiomyolipomas in patients with tuberous sclerosis complex. The drug previously was approved for patients with advanced renal cell cancer who failed to respond to treatment with Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals' Nexavar or Pfizer's Sutent. Medscape (free registration) (4/26), Fox Business/Dow Jones Newswires (4/26) Share: Email
GSK's soft-tissue sarcoma drug Votrient gains FDA approval
GlaxoSmithKline's Votrient obtained FDA approval to treat patients with soft-tissue sarcoma who already received chemotherapy. Votrient has orphan-drug status, giving GSK seven years of market exclusivity. Reuters (4/26) Share: Email
FDA panel will review Onyx's myeloma drug carfilzomib June 20
Onyx Pharmaceuticals said an FDA advisory panel is set to meet June 20 to review carfilzomib as treatment for relapsed and refractory multiple myeloma. The FDA has until July 27 to decide whether to approve the drug. MyelomaBeacon.com (4/26) Share: Email
FDA user fee act is an opportunity to maintain innovation
America's medical research system operates like an ecosystem with four vital components: intellectual property protection, open access to markets, free-market pricing and a predictable regulatory system, writes Eli Lilly & Co. CEO John Lechleiter. With reauthorization of the Prescription Drug User Fee Act, Congress has an opportunity to "achieve a higher standard of transparency and accountability at the FDA, and provide the agency with the resources it needs to keep pace with emerging medical discoveries," Lechleiter writes. Forbes (4/25) Share: Email
 
Repligen announces setback for pancreatic drug
The FDA called off a May 31 panel meeting regarding Repligen's new-drug application for RG1068, an imaging agent that spots abnormalities in pancreatic ducts. "We intend to continue our dialogue with the FDA to assess a potential path forward for RG1068," CEO Walter Herlihy said. The Wall Street Journal (tiered subscription model) (4/26) Share: Email
Other News
Pat Croce Reveals His Insights for Acting on Your Passion
If you're ready to "get your butt off the couch and get into the game of life," it's time to get inspired by this successful entrepreneur and leadership expert. Read the featured article.

Global Focus
EndoSphere obtains EU approval for anti-obesity device
EndoSphere has earned CE Mark approval to market an incisionless anti-obesity device, called Satisphere, in Europe. The device, which is implanted in the small intestine via an endoscope, is designed to help patients shed excess weight without the need for drugs or surgery. MedCityNews.com (4/26) Share: Email
Food & Dietary Supplements
Senate committee raises FDA's discretionary fund
The Senate Appropriations Committee has cleared a $22 million increase in the FDA's discretionary budget for fiscal year 2013. The boost in funding approved by the group is allocated specifically for the enforcement of the Food Safety Modernization Act, according to the committee. "This funding level takes into consideration the federal government's responsibilities to protect public health and safety, especially in the areas of food, drugs, medical devices and biologics," the committee said. FoodSafetyNews.com (4/27) Share: Email
Other News
Business Tips and Advice
Sponsored Content from American Express
Medical Devices
Bill seeking stronger FDA oversight of medical devices advances
A Senate panel on Wednesday cleared a bill that would allow the FDA to evaluate the safety of approved medical devices and give conditional approvals dependent on further studies. The measure also would tighten the agency's 510(k) process that permits firms to prove the similarity of their devices to products already approved without needing extensive trials. MassDevice.com (Boston) (4/25) Share: Email
Latest version of GE's cardiovascular ultrasound wins FDA nod
GE Healthcare has received FDA clearance for Vivid E9 Breakthrough 2012, the latest version of its cardiovascular ultrasound device. The newly approved product, which features a 4D transducer, is designed for use in transeophageal echocardiography, mitral valve repair and related procedures. HealthImaging.com (4/30) Share: Email
FDA approves advanced laser sheath from Spectranetics
The FDA has given Spectranetics approval for its next-generation GlideLight Laser Sheath. The device allows more accurate control and less force for safer extraction of cardiac leads. Reuters (4/25) Share: Email
HeartWare's cardiac pump gains support of FDA panel
A panel of FDA advisers voted in favor of approving the HeartWare ventricular assist device, a blood pump tailored for use in severe heart failure patients awaiting transplants. The panel concluded that the device was helpful in saving lives, but urged HeartWare to run additional safety studies if it obtains FDA approval. Reuters (4/26) Share: Email
Tobacco
Major tobacco firms fund fight against Prop 29 in Calif.
R.J. Reynolds and Philip Morris are contributing to a campaign to vote down Proposition 29, which would impose a $1 tax increase to packs of cigarettes sold in California. The measure would enable the state to generate funds for cancer research. The new tax is estimated to translate to a yearly loss of $1 billion in tobacco sales. San Jose Mercury News (Calif.) (free registration) (4/27) Share: Email
FDLI Items
Don't miss Introduction to Medical Device Law in Palo Alto, Calif., in June
Whether you are a new professional in the medical device industry or seasoned regulatory affairs or legal professional needing a refresher on current FDA medical device regulatory developments, you will benefit from attending this in-depth, interactive two-day course. Attendees will hear from experts who will review the essential elements of medical device regulation. Register today to save. Share: Email
 
theLINK: A Comprehensive FDA Directory -- save $250 on your online subscription
FDLI's FDA directory, theLINK, is a comprehensive directory of FDA employees and select employees of other agencies including USDA, FTC, CMS, CDC and AHRQ. Its unique functionality makes it a must-have, go-to resource for companies, law firms, libraries and every food and drug law professional. theLINK is continuously updated, well organized, accessible in print and online, and has detailed information on the roles and duties of employees and offices. Learn more and save up to $250 on your new subscription. Share: Email
 
JOBS
powered by
Junior to Mid-Level FDA & Healthcare Associate
MORGAN LEWIS - Washington, DC
Senior and Principal P/T Consultants
BECKER & ASSOCIATES CONSULTING - Nationwide, SL_Nationwide
SmartQuote
Knowledge comes, but wisdom lingers.
Alfred, Lord Tennyson,
British poet
 Share: Email
Learn more about FDLI ->About FDLI | Join FDLI | Conferences | Publications
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828
Jobs Contact:  Elizabeth Stack
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information